Penetrable Nanoplatform for “Cold” Tumor Immune Microenvironment Reeducation

Abstract Lack of tumor‐infiltration lymphocytes (TILs) and resistances by overexpressed immunosuppressive cells (principally, myeloid‐derived suppressor cells (MDSCs)) in tumor milieu are two major challenges hindering the effectiveness of immunotherapy for “immune‐cold” tumors. In addition, the nat...

Full description

Bibliographic Details
Main Authors: Qinjun Chen, Yongqing He, Yu Wang, Chao Li, Yujie Zhang, Qin Guo, Yiwen Zhang, Yongchao Chu, Peixin Liu, Hongyi Chen, Zheng Zhou, Wenxi Zhou, Zhenhao Zhao, Xiaomin Li, Tao Sun, Chen Jiang
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202000411
Description
Summary:Abstract Lack of tumor‐infiltration lymphocytes (TILs) and resistances by overexpressed immunosuppressive cells (principally, myeloid‐derived suppressor cells (MDSCs)) in tumor milieu are two major challenges hindering the effectiveness of immunotherapy for “immune‐cold” tumors. In addition, the natural physical barrier existing in solid cancer also limits deeper delivery of drugs. Here, a tumor‐targeting and light‐responsive‐penetrable nanoplatform (Apt/PDGs^s@pMOF) is developed to elicit intratumoral infiltration of cytotoxic T cells (CTLs) and reeducate immunosuppressive microenvironment simultaneously. In particular, porphyrinic metal–organic framework (pMOF)–based photodynamic therapy (PDT) induces tumor immunogenic cell death (ICD) to promote CTLs intratumoral infiltration and hot “immune‐cold” tumor. Upon being triggered by PDT, the nearly 10 nm adsorbed drug‐loaded dendrimer de‐shields from the nanoplatform and spreads into the deeper tumor, eliminating MDSCs and reversing immunosuppression, eventually reinforcing immune response. Meanwhile, the designed nanoplatform also has a systemic MDSC inhibition effect and moderate improvement of overall antitumor immune responses, resulting in effective suppression of distal tumors within less significant immune‐related adverse effects (irAEs) induced.
ISSN:2198-3844